Chronic Administration of Methamphetamine Aggravates
Atherosclerotic Vulnerable Plaques in Apolipoprotein E Knockout
Mice Fed with a High-cholesterol Diet

Xiaoxue      Cui; Bo      Gao; Yijun      Yu; Ye      Gu; Liqun      Hu

doi:10.2174/1566524023666230321095233

Abstract

Background: It has been observed previously that chronic methamphetamine (METH) administration could upregulate neuropeptide Y (NPY) expression and promote atherosclerotic formation in apolipoprotein E knockout (ApoE-/-) mice fed with a normal cholesterol or high diet and NPY might be involved in the pathogenesis of METHinduced atherogenic effects through NPY Y1 receptor pathway. Vulnerable coronary atherosclerotic plaque (VP) is a critical pathological finding responsible for the acute coronary syndrome (ACS). In this study, we explored whether METH abuse could aggravate the formation of VP in ApoE-/- mice fed with high cholesterol diet.

Objective: The purpose of this study was to observe if chronic METH administration could aggravate vulnerable plaque (VP) formation in ApoE-/- mice fed with a highcholesterol diet.

Methods: Male ApoE-/- mice fed with a high-cholesterol diet were intraperitoneally injected with normal saline (NS) or 8 mg/kg/day METH (M8) for 24 weeks. Body weight was monitored from baseline to 24 weeks at 2 weeks intervals. After 24 weeks of treatment, plasma lipid variables were measured. Movat's staining and immunohistochemical staining were performed on frozen sections of the aortic roots to calculate VP percentage and intraplaque hemorrhage (IPH) percentage and detect expression of NPY, vascular endothelial growth factor (VEGF), and CD31. In vitro, the expressions of Y2R, VEGF, and CD31 were detected by immunofluorescence staining in aortic endothelial cells incubated with PBS, 100μM METH, 10nmol NPY, or 100μM METH plus 10nmol NPY for 12 hours.

Results: The CD31 positive area, percentage of IPH, VP, and the expressions of NPY and VEGF were significantly increased in the M8 group than in the NS group. In vitro, the expressions of Y2R, VEGF, and CD31 were significantly increased in the METH+NPY group than in the PBS, METH, and NPY groups and these effects could be blunted by treatment with a Y2R antagonist or DPPIV inhibitor.

Conclusion: Chronic METH administration could aggravate VP in ApoE-/- mice fed with a high-cholesterol diet, possibly through upregulating vascular NPY and VEGF expression and promoting angiogenesis and vessel rupture in atherosclerotic plaques. Our findings indicated that increased VP formation might contribute to the development of acute coronary syndrome post-chronic METH abuse by activating DPPIV/NPY/Y2R pathway.

Keywords: Methamphetamine, vulnerable plaque, neuropeptide Y, intraplaque hemorrhage, dipeptidyl peptidase IV, neuropeptide Y Y2 receptor.

« Previous Next »

[1]
Kaye S, Darke S, Duflou J, McKetin R. Methamphetamine-related fatalities in Australia: Demographics, circumstances, toxicology and major organ pathology. Addiction  2008; 103(8): 1353-60.
 [http://dx.doi.org/10.1111/j.1360-0443.2008.02231.x] [PMID:  18855825]

[2]
Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA. Frequency of acute coronary syndrome in patients presenting to the Emergency Department with chest pain after methamphetamine use. J Emerg Med  2003; 24(4): 369-73.
 [http://dx.doi.org/10.1016/S0736-4679(03)00031-3] [PMID:  12745036]

[3]
Gao B, Li L, Zhu P, et al. Chronic administration of methamphetamine promotes atherosclerosis formation in ApoE−/− knockout mice fed normal diet. Atherosclerosis  2015; 243(1): 268-77.
 [http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.001] [PMID:  26409626]

[4]
Zhu P, Li L, Gao B, et al. Impact of chronic methamphetamine treatment on the atherosclerosis formation in ApoE−/− mice fed a high cholesterol diet. Oncotarget  2017; 8(33): 55064-72.
 [http://dx.doi.org/10.18632/oncotarget.19020] [PMID:  28903402]

[5]
Gonçalves J, Baptista S, Olesen MV, et al. Methamphetamine-induced changes in the mice hippocampal neuropeptide Y system: implications for memory impairment. J Neurochem  2012; 123(6): 1041-53.
 [http://dx.doi.org/10.1111/jnc.12052] [PMID:  23061411]

[6]
Lagraauw HM, Westra MM, Bot M, et al. Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation. Atherosclerosis  2014; 235(1): 196-203.
 [http://dx.doi.org/10.1016/j.atherosclerosis.2014.04.025] [PMID:  24858338]

[7]
Li L, Najafi AH, Kitlinska JB, et al. Of mice and men: Neuropeptide Y and its receptors are associated with atherosclerotic lesion burden and vulnerability. J Cardiovasc Transl Res  2011; 4(3): 351-62.
 [http://dx.doi.org/10.1007/s12265-011-9271-5] [PMID:  21468772]

[8]
Hirsch D, Zukowska Z. NPY and stress 30 years later: The peripheral view. Cell Mol Neurobiol  2012; 32(5): 645-59.
 [http://dx.doi.org/10.1007/s10571-011-9793-z] [PMID:  22271177]

[9]
Segal DS, Kuczenski R, O’Neil ML, Melega WP, Cho AK. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology  2003; 28(10): 1730-40.
 [http://dx.doi.org/10.1038/sj.npp.1300247] [PMID:  12865898]

[10]
Najafi AH, Aghili N, Tilan JU, et al. A new murine model of stress-induced complex atherosclerotic lesions. Dis Model Mech  2013; 6(2): dmm.009977.
 [http://dx.doi.org/10.1242/dmm.009977] [PMID:  23324329]

[11]
Vendrov AE, Stevenson MD, Alahari S, et al. Attenuated superoxide dismutase 2 activity induces atherosclerotic plaque instability during aging in hyperlipidemic mice. J Am Heart Assoc  2017; 6(11): e006775.
 [http://dx.doi.org/10.1161/JAHA.117.006775] [PMID:  29079564]

[12]
Chen F, Zhou Y, Yang K, Shen M, Wang Y. NPY stimulates cholesterol synthesis acutely by activating the SREBP2-HMGCR pathway through the Y1 and Y5 receptors in murine hepatocytes. Life Sci  2020; 262: 118478.
 [http://dx.doi.org/10.1016/j.lfs.2020.118478] [PMID:  32976883]

[13]
Zhu P, Sun W, Zhang C, Song Z, Lin S. The role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease. Int J Cardiol  2016; 220: 235-41.
 [http://dx.doi.org/10.1016/j.ijcard.2016.06.138] [PMID:  27389447]

[14]
Bruinstroop E, Pei L, Ackermans MT, et al. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes  2012; 61(5): 1043-50.
 [http://dx.doi.org/10.2337/db11-1142] [PMID:  22461566]

[15]
Della-Morte D, Dong C, Crisby M, et al. Association of carotid plaque morphology and glycemic and lipid parameters in the northern manhattan study. Front Cardiovasc Med  2022; 9: 793755.
 [http://dx.doi.org/10.3389/fcvm.2022.793755] [PMID:  35141303]

[16]
Fonseca FAH, de Oliveira Izar MC. High-sensitivity C-reactive protein and cardiovascular disease across countries and ethnicities. Clinics  2016; 71(4): 235-42.
 [http://dx.doi.org/10.6061/clinics/2016(04)11] [PMID:  27166776]

[17]
Hu S, Liu Y, You T, Zhu L. Semaphorin 7A promotes VEGFA/VEGFR2-mediated angiogenesis and intraplaque neovascularization in ApoE-/- mice. Front Physiol  2018; 9: 1718.
 [http://dx.doi.org/10.3389/fphys.2018.01718] [PMID:  30555351]

[18]
Lee EW, Michalkiewicz M, Kitlinska J, et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest  2003; 111(12): 1853-62.
 [http://dx.doi.org/10.1172/JCI16929] [PMID:  12813021]

[19]
Ventura F, Muga M, Coelho-Santos V, Fontes-Ribeiro CA, Leitão RA, Silva AP. Protective effect of neuropeptide Y2 receptor activation against methamphetamine-induced brain endothelial cell alterations. Toxicol Lett  2020; 334: 53-9.
 [http://dx.doi.org/10.1016/j.toxlet.2020.09.013] [PMID:  32956829]

[20]
Movafagh S, Hobson JP, Spiegel S, et al. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J  2006; 20(11): 1924-6.
 [http://dx.doi.org/10.1096/fj.05-4770fje] [PMID:  16891622]

[21]
Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med  2003; 349(24): 2316-25.
 [http://dx.doi.org/10.1056/NEJMoa035655] [PMID:  14668457]

[22]
Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: Agiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol  2005; 25(10): 2054-61.
 [http://dx.doi.org/10.1161/01.ATV.0000178991.71605.18] [PMID:  16037567]

[23]
Chistiakov DA, Orekhov AN, Bobryshev YV. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability. Acta Physiol  2015; 213(3): 539-53.
 [http://dx.doi.org/10.1111/apha.12438] [PMID:  25515699]

[24]
Parma L, Baganha F, Quax PHA, de Vries MR. Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis. Eur J Pharmacol  2017; 816: 107-15.
 [http://dx.doi.org/10.1016/j.ejphar.2017.04.028] [PMID:  28435093]

[25]
Michel JB, Thaunat O, Houard X, Meilhac O, Caligiuri G, Nicoletti A. Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol  2007; 27(6): 1259-68.
 [http://dx.doi.org/10.1161/ATVBAHA.106.137851] [PMID:  17395854]

[26]
Michel JB, Martin-Ventura JL, Nicoletti A, Ho-Tin-Noé B. Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis  2014; 234(2): 311-9.
 [http://dx.doi.org/10.1016/j.atherosclerosis.2014.03.020] [PMID:  24726899]

Rights & Permissions Print Cite

Article Metrics

33

3

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1566524023666230321095233	Print ISSN 1566-5240
Publisher Name Bentham Science Publisher	Online ISSN 1875-5666

Current Molecular Medicine

Chronic Administration of Methamphetamine Aggravates Atherosclerotic Vulnerable Plaques in Apolipoprotein E Knockout Mice Fed with a High-cholesterol Diet

Abstract

Related Journals

Related Books